Glioma, Malignant Clinical Trial
Official title:
Identification of the Immuno Suppressive Characteristics of Glioma Patients by an Integrated Radio-immunological Approach
The most aggressive primary brain tumors in adults, glioblastomas, are characterized by a profound local and systemic immune suppression. During tumor progression, the infiltration of inflammatory leukocytes, especially of myeloid origin, endowed with immunosuppressive function is observed. Aim of this study is to evaluate myeloid cell infiltrate and iron metabolism in tumor-associated macrophages by combining a multimodal MRI imaging technique with immunophenotyping of the tumor microenvironment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05557240 -
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
|
N/A | |
Recruiting |
NCT05474573 -
Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases
|
N/A | |
Recruiting |
NCT05485038 -
General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas
|
N/A | |
Active, not recruiting |
NCT04547621 -
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
Completed |
NCT05806619 -
Glioma: Biomolecular Aspects
|
||
Not yet recruiting |
NCT04562077 -
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
|
||
Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
Completed |
NCT04497142 -
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
|
Phase 1/Phase 2 | |
Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05656053 -
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
|
||
Recruiting |
NCT06196918 -
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
|
N/A | |
Recruiting |
NCT05556486 -
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
|
||
Recruiting |
NCT05406700 -
Niraparib In Recurrent IDH 1/2 Gliomas
|
Early Phase 1 | |
Recruiting |
NCT05773326 -
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
|
Early Phase 1 | |
Active, not recruiting |
NCT05063682 -
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
|
Phase 1 | |
Completed |
NCT05100173 -
Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
|
||
Completed |
NCT05100602 -
Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
|
||
Recruiting |
NCT05182905 -
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
|
Early Phase 1 | |
Recruiting |
NCT06381726 -
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
|
N/A |